Aptus Pharma

APPL

Q: How strong is Aptus Pharma balance sheet?

Balance sheet of Aptus Pharma is strong.It shouldn't have solvency or liquidity issues.

Q: Is the debt of Aptus Pharma increasing or decreasing?

The net debt of Aptus Pharma is decreasing.Latest net debt of Aptus Pharma is ₹0.69 Crs as of Mar-25.This is less than Mar-24 when it was ₹4.25 Crs.

Q: Is Aptus Pharma stock expensive?

There is insufficient historical data to gauge this.Latest PE of Aptus Pharma is 28.59

Price

Nano Cap

₹92 Cr.

New to Zerodha? Sign-up for free.

Aptus Pharma operates as a marketing and distribution company for finished pharmaceutical products. It utilizes a contract manufacturing model to offer a wide array of medications across various therapeutic areas, including anti-infectives, gastrointestinal treatments, antacids, and products for anti-allergic and respiratory needs.

Aptus Pharma operates as a marketing and distribution company for finished pharmaceutical products.… More

Low

80.80

52W Range

High

145

29.63

Sector PE

27.11

P/B

13.21

Div.Yield

ROE

44.5%

EBIDTA

ROCE

47.76

EPS

New to Zerodha? Sign-up for free.

Share Price
Financials
Revenue mix
Shareholdings
Peers
Forensics

This data is currently unavailable for this company.

Summary
Profit & Loss
Balance sheet
Cashflow

View Detailed Summary

This data is currently unavailable for this company.

Yearly | Quarterly

(In Cr.)

(In Cr.)
This data is currently unavailable for this company.

Financial Ratio's

(In %)

Detailed P&L Report

(In Cr.)

Detailed Balance Sheet

Financial Year (In Cr.)

Detailed Cash Flow

Product wise
Location wise

None
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

None
Revenue Mix

Latest

Historic

This data is currently unavailable for this company.

More Info

Shareholdings

Holders

Detailed Shareholdings

This data is currently unavailable for this company.

Peers

Detailed Peers

Forensics

View Detailed Forensics

Recent events

News
Corporate Actions

This data is currently unavailable for this company.

More Nano Cap Ideas

See similar 'Nano' cap companies with recent activity

Promoter Buying

Companies where the promoters are bullish

Detailed List

Capex

Companies investing on expansion

Detailed List

Superstar Investor

Companies where well known investors have invested

Detailed List

Popular questions

Business
Financials
Share Price
Shareholdings

What does Aptus Pharma do?

Aptus Pharma is engaged in the business of marketing, and distribution of finished pharmaceutical formulations. It operates through a contract manufacturing model. It provides a diverse range of pharmaceutical products catering to various therapeutic categories including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, etc.

Who are the competitors of Aptus Pharma?

Aptus Pharma major competitors are Zota Health Care, Sunrest Lifescience, Lincoln Pharma. Market Cap of Aptus Pharma is ₹89 Crs. While the median market cap of its peers are ₹1,063 Crs.

Is Aptus Pharma financially stable compared to its competitors?

Aptus Pharma seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

Does Aptus Pharma pay decent dividends?

The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aptus Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

How has Aptus Pharma allocated its funds?

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Inventory

How strong is Aptus Pharma balance sheet?

Balance sheet of Aptus Pharma is strong. It shouldn't have solvency or liquidity issues.

Is the profitablity of Aptus Pharma improving?

Yes, profit is increasing. The profit of Aptus Pharma is ₹3.1 Crs for Mar 2025, ₹0.8 Crs for Mar 2024 and ₹0.19 Crs for Mar 2023

Is the debt of Aptus Pharma increasing or decreasing?

The net debt of Aptus Pharma is decreasing. Latest net debt of Aptus Pharma is ₹0.69 Crs as of Mar-25. This is less than Mar-24 when it was ₹4.25 Crs.

Is Aptus Pharma stock expensive?

There is insufficient historical data to gauge this. Latest PE of Aptus Pharma is 28.59

Has the share price of Aptus Pharma grown faster than its competition?

There is not enough historical data for the companies share price.

Is the promoter bullish about Aptus Pharma?

Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Aptus Pharma is 72.89% and last quarter promoter holding is 72.89%.

Are mutual funds buying/selling Aptus Pharma?

There is Insufficient data to gauge this.

APPL

Share Price

Financials

Revenue mix

Shareholdings

Peers

Forensics

Summary

Profit & Loss

Balance sheet

Cashflow

Product wise

Location wise

Recent events

News

Corporate Actions

More Nano Cap Ideas

Promoter Buying

Capex

Superstar Investor

Popular questions

Business

Financials

Share Price

Shareholdings

What does Aptus Pharma do?

Who are the competitors of Aptus Pharma?

Is Aptus Pharma financially stable compared to its competitors?

Does Aptus Pharma pay decent dividends?

How has Aptus Pharma allocated its funds?

How strong is Aptus Pharma balance sheet?

Is the profitablity of Aptus Pharma improving?

Is the debt of Aptus Pharma increasing or decreasing?

Is Aptus Pharma stock expensive?

Has the share price of Aptus Pharma grown faster than its competition?

Is the promoter bullish about Aptus Pharma?

Are mutual funds buying/selling Aptus Pharma?